Fructose is a major component of dietary sugar and its overconsumption exacerbates key pathological features of metabolic syndrome. The central fructose-metabolising enzyme is ketohexokinase (KHK), which exists in two isoforms: KHK-A and KHK-C, generated through mutually exclusive alternative splicing of KHK pre-mRNAs. KHK-C displays superior affinity for fructose compared with KHK-A and is produced primarily in the liver, thus restricting fructose metabolism almost exclusively to this organ. Here we show that myocardial hypoxia actuates fructose metabolism in human and mouse models of pathological cardiac hypertrophy through hypoxia-inducible factor 1a (HIF1a) activation of SF3B1 and SF3B1-mediated splice switching of KHK-A to KHK-C. Heart-specific depletion of SF3B1 or genetic ablation of Khk, but not Khk-A alone, in mice, suppresses pathological stress-induced fructose metabolism, growth and contractile dysfunction, thus defining signalling components and molecular underpinnings of a fructose metabolism regulatory system crucial for pathological growth.
. The ensuing state of hypoxia activates hypoxia-inducible factor (HIF)1a that mediates adaptive transcriptional responses to low-oxygen tension 3 to support cardiomyocyte growth, myocardial angiogenesis and reprogramming of metabolism 4 . Unremitted pathologic stress leads ultimately to functional deterioration of the heart with the clinical signs and symptoms of heart failure 5 . Given that both HIF1a transcription and alternative pre-mRNA splicing are central to the control of metabolism, we embarked on a systematic and functional analysis of HIF1a-dependent splice factor expression and pre-mRNA splicing in pathologic cardiac hypertrophy. We identified splice factors as HIF1a targets, which prompted the analysis of their RNA targets, unveiling mechanistic and functional linkages between HIF1a, splice factor 3b subunit 1 (SF3B1), KHK-C splice isoform production and fructose metabolism in cardiac hypertrophy.
The HIF1a-SF3B1-KHK-C axis
To deduce changes in both gene expression and alternative splicing as a function of Hif1a, we followed the experimental workflow illustrated in Extended Data Fig. 1a . RNA isolated from normoxic and hypoxic neonatal mouse cardiomyocytes (NMCs), depleted (or not) of Hif1a by specific short hairpin RNAs (shHif1a), was subjected to a splice-junction microarray analysis. Genes exhibiting a Hif1a-dependent expression profile were manually checked for an involvement in pre-mRNA splicing and, in parallel, matched to a list of 329 unique genes comprised of validated and in silico-predicted splice factors [6] [7] [8] (Supplementary Fig. 1 and Supplementary Table 1) . Twenty genes with characteristics of splice factors/regulators displayed a Hif1a-dependent expression pattern (Fig. 1a) , of which four, C1qbp, Hnrnph3, Jmjd6 and Sf3b1, contained conserved hypoxia-responsive elements (HREs) in their promoters (Extended Data Fig. 1b) .
Data derived from the splice-junction microarray analysis were also interrogated for changes in gene splicing as a function of Hif1a and further filtered for their potential association to metabolism, leading to Ard1 (also known as Naa10), Hk1, Khk, and Pfkfb3, which exhibited the most consistent and significant changes (Fig. 1b) . TheHIF1a targets and hypertrophic markers were also induced (Extended Data Fig. 1q and Supplementary Fig. 3d ). Thus, HIF1a, SF3B1 and KHK-C are coordinately upregulated in different mouse models of cardiac hypertrophy and biopsies of human cardiomyopathy patients.
The HIF1a target SF3B1 mediates splicing of KHK Sf3b1 appears to represent a direct Hif1a target. First, treatment of NMCs with phenylephrine or isoproterenol, known inducers of Hif1a and Hif1a-target genes 10 , increased Sf3b1 mRNA expression in a Hif1a-dependent manner (Extended Data Fig. 2a) . Second, Sf3b1 mRNA expression also increased upon depletion of the Von HippelLindau protein (pVhl) or ectopic expression of HIFla lacking the oxygen-dependent degradation domain (HIF1aDODD) (Extended Data Fig. 2b) . Third, the promoter of SF3B1 contains a highly conserved HRE (Extended Data Fig. 2c ). Fourth, expression of HIF1aDODD activated a mouse wild-type Sf3b1-promoter-luciferase reporter but not the corresponding reporter harbouring a mutant HRE (Fig. 2a) . Fifth, chromatin immunoprecipitation (ChIP) assays demonstrate an association of Hif1a with the HRE in the Sf3b1 promoter in native chromatin (Fig. 2b) .
Next we measured the incorporation of radioactively labelled [ 3 H]leucine in NMCs depleted of Sf3b1 and exposed to various treatments including phenylephrine or isoproterenol (Extended Data Fig. 2d ), expression of HIF1aDODD (Extended Data Fig. 2e ), hypoxia (Extended Data Fig. 2f ) or simultaneous depletion of pVhl (Extended Data Fig. 2g ). We observed that [ 3 H]leucine incorporation (Extended Data Fig. 2i-k) , a/b myosin heavy chain mRNA ratio (Extended Data Fig. 2l -o) and cell size (Extended Data Fig. 2p ) changed as a function of Sf3b1. Other components of the U2 small nuclear ribonucleoprotein (U2 snRNP) complex, namely Sf3b2, Sf3b3 and Sf3a3, neither increased in abundance in response to Hif1a expression nor did they affect, when downregulated by different shRNAs, to a measurable extent, Hif1a-stimulated cell growth (Extended Data Fig. 2q , r and Supplementary Fig. 4) .
Also, known parameters of Hif1a-driven metabolism including extracellular acidification rate (ECAR; an indicator lactate production) and oxygen consumption rate (OCR; an indicator of oxidative phosphorylation) changed in a Sf3b1-dependent manner in NMCs.
At basal levels, ECAR was not affected by depletion of Sf3b1 but increased upon addition of isoproterenol (Extended Data Fig. 2s, t) . OCR was repressed, as expected, in isoproterenol-treated cells upon addition of either oleic acid or carbonyl cyanide-4-(trifluoromethoxy)-phenylhydrazone, an effect diminished by depletion of Sf3b1 (Extended Data Fig. 2u ). Ectopic expression of HIF1aDODD produced similar effects on ECAR and OCR as isoproterenol (Extended Data Fig. 2v-z) , while depletion of Sf3b1 alone had no effect ( Supplementary Fig. 5 ). In sum, these results suggest a key contributory role for Sf3b1 in Hif1a-mediated growth and metabolic programs.
Sf3b1 participates in the catalysis of splicing 11 , can be crosslinked to the 59 and 39 of the branch point adenosine 12 , and displays differential effects on specific splice targets under conditions of reduced function 13, 14 . Indeed, splice-junction analysis revealed widespread effects on both alternative splicing and gene expression that included changes in Khk isoform expression when Sf3b1 was depleted in hypoxic NMCs (Supplementary Tables 2 and 3) . RNA-immunoprecipiations of Sf3b1 from extracts of NMCs exposed to hypoxia or HIF1aDODD overexpression, demonstrate that Sf3b1 occupies RNA sequences upstream of exon 3C (and not of exon 3A) of Khk pre-mRNA in hypoxia but not normoxia (Fig. 2c) . Upon depletion of Hif1a, Sf3b1 was redirected towards branch-point sequences of exon 3A (Fig. 2c) . This suggests that Sf3b1 association with RNA sequences upstream of exon 3C of Khk requires Hif1a-signalling.
Sf3b1 acts as a direct mediator of Khk splicing as its overexpression caused a shift from Khk-A to Khk-C (Extended Data Fig. 3a) . Selective depletion of endogenously (but not exogenously) produced Sf3b1 prevented this shift (Extended Data Fig. 3a) . Quantitative PCR (qPCR) analysis confirmed the overexpression and/or reduction of Sf3b1 mRNAs where expected (Extended Data Fig. 3b) . Concomitant with the shift in Khk isoform expression towards Khk-C, cell growth was induced (Extended Data Fig. 3c ). Neither the overproduction of SF3A3 or SF3B3 (Extended Data Fig. 3d, e) , nor the depletion of Sf3a3, Sf3b3 or Sf3b2 by corresponding shRNAs, generated a similar robust splice shift towards Khk-C despite efficient depletion of the respective proteins (Extended Data Fig. 3f, g and Supplementary Fig. 4 ). Cell growth was also not affected by SF3A3 or SF3B3 expression (Extended Data Fig. 3h ). controls were assessed for SF3B1, KHK-A and KHK-C expression by qPCR (n 5 16 for patient samples and n 5 6 for controls; error bars are s.e.m.; **P , 0.01; ***P , 0.001; two-tailed unpaired t-test). g, Top, schematic representation of exon 2 to 5 of human KHK. Alternative usage of exon 3 (Ex3 alt.) is displayed in blue (exon 3A) and red (exon 3C). Primer sets location and orientation used for RT-PCR analysis, are indicated with arrows. Bottom, assessment of KHK-A and KHK-C expression by RT-PCR in ventricles of controls and HCM patients using primer set 1 and 2 as described above. h, Lysates of left-ventricular samples from healthy controls and aortic stenosis or HCM patients were processed for immunoblotting with antibodies against denoted proteins.
Next we proceeded with mass-spectrometry-based metabolomic profiling of hexose-phosphates in NMCs expressing HIF1aDODD in the absence or presence of shSf3b1. We observed profoundly increased levels of fructose-1-phosphate (F1P) and glucose-6-phosphate in response to HIF1a activation (Fig. 2d) , but only the level of the former was Sf3b1-dependent (Fig. 2d) . In accord with increased levels of F1P, HIF1aDODD also increased total cellular Khk activity by 3.6-fold compared to control NMCs (Fig. 2e) . In a comparative analysis, overexpressed human KHK-C displayed, in NMCs depleted for endogenous Khk, a 3.7-fold higher kinase activity than KHK-A (Extended Data Fig. 3i, j) . Thus, activation of the Hif1a-Sf3b1 axis activates Khk-C to stimulate F1P production.
To assess whether increased levels of F1P are derived from external fructose or from conversion of glucose via the polyol pathway 15 Data Fig. 3k ). Glut5 fructose transporter mRNA expression was likewise induced by KHK-C and HIF1aDODD (Extended Data Fig. 3l) .
Khk-C is also a critical downstream mediator of Hif1a-induced cell growth as selective depletion of Khk-C, but not Khk-A, rescued HIF1aDODD-induced cardiomyocyte growth ( Fig. 2g and Extended Data Fig. 3m ). Knockdown efficiency and isoform specificity of the corresponding shRNAs targeting Khk isoforms was confirmed by qPCR (Extended Data Fig. 3n ). Taken together, Sf3b1 appears to be a direct mediator of Khk pre-mRNA splicing, resulting in Khk-C expression, increased Khk activity, fructose uptake and cell growth.
Expression of KHK-C promotes anabolic metabolism
To characterize metabolic phenotypes in NMCs associated with activation of the HIF1a-SF3B1-KHK-C axis and as a function of fructose availability, we performed metabolomic profiling. These efforts established the following experimental points. First, in the presence of fructose and glucose, HIF1aDODD expression increased glycolysis (for example, hexose-phosphates), amino acid metabolism and biosynthesis (for example, dexfosfoserine, aspartate, arginine), the non-oxidative pentose-phosphate pathway (PPP; for example, sedoheptulose-7-phosphate, pentose phosphates) and to a lesser degree also the oxidative PPP (for example, 6-phospho-D-gluconate, pentose phosphates) and intermediates of DNA/RNA biosynthesis (for example, N-formyl-GAR, folate, deoxyuridine) (Fig. 3) . Changes in redox balance are exemplified by lower levels of NADPH, NADH and of the reduced state of glutathione (GSSG) (Fig. 3, lanes 4 and 5) . Reduced levels of these metabolites are probably the result of extensive utilization of reducing equivalents for macromolecular biosynthesis 16 . Second, depletion of Khk-C (but not Khk-A) reverted HIF1aDODD-induced metabolic changes (Fig. 3 , compare lane 11 with 5 and 4), while its overexpression mimicked them (Fig. 3 , compare lane 123 and 425). Third, when KHK-C was overexpressed under fructoselacking conditions, levels of glycolytic and PPP metabolites decreased and the reduction of NADPH and NADH was less pronounced (Fig. 3 , compare lane 2 and 3; Extended Data Fig. 4a ). Hence, exogenous fructose contributes significantly to the metabolic effects mediated by Khk-C.
In accord with the above, we detected [ Data Fig. 4d ). Increasing glucose availability in the presence of fructose had similar effects (Extended Data Fig. 4d ). Immunoblotting confirmed the expected expression pattern of KHK-A and KHK-C ( Supplementary Fig. 6a ). These results suggest a critical role for KHK-C in HIF1a-dependent metabolic reprogramming and growth.
Since phosphorylation of fructose by Khk-C is unrestrained, it could contribute to ATP-depletion as shown previously in liver 17 , I n p u t I g G I P I n p u t I g G I P I n p u t I g G I P I n p u t I g G I P 
RESEARCH ARTICLE
thereby limiting ATP-driven allosteric inactivation of glycolysis at the level of phosphofructokinase (PFK) 18, 19 . When HIF1aDODD was overexpressed in NMCs, the ADP/ATP ratios increased (Extended Data Fig. 4e ). Simultaneous depletion of either Sf3b1 or Khk-C (but not Khk-A) prevented this (Extended Data Fig. 4e ). Khk-C but not Khk-A, when overexpressed, enhanced ADP/ATP ratios (Extended Data Fig. 4e ). Thus, activation of the HIF1a-SF3B1-KHK-C axis increases ADP/ATP ratios.
Hypoxia or activation of HIF1a drives an accumulation of lipids in heart hypertrophy 10, 20 . Since the F1P product DHAP is important for formation of the glycerol backbone in triglyceride synthesis, we tested the Khk-C-dependency of this phenomenon by Oil Red O staining of lipid droplets in oleic-acid-treated NMCs. Overexpression of HIF1aDODD or exposure to hypoxia induced lipid droplet formation, which was prevented upon depletion of Khk-C but not Khk-A (Extended Data Fig. 4f-h ). Similar results were obtained when lipid levels were quantified with Nile Red ( Supplementary Fig. 6b , c). Khk-C, but not Khk-A, was also required for phenylephrineinduced lipid accumulation ( Supplementary Fig. 6d ). Fructose carbon contributes to triglyceride synthesis in NMCs as measured by the amount of fructose-derived [ 3 H] in the lipid fraction of NMCs expressing HIF1aDODD (Supplementary Fig. 6e ). Downregulation of Khk-A had no effect, but depletion of either Khk-C, Glut5 or Sf3b1 prevented HIF1a-driven conversion of fructose carbon into lipids ( Supplementary Fig. 6e, f) . In a gain-of-function experiment, overexpression of KHK-C promoted fructose carbon to lipid conversion while KHK-A expression did not ( Supplementary Fig. 6e ).
We also investigated the contribution of the two different Khkisoforms to Hif1a-driven changes in OCR and ECAR in NMCs (Extended Data Fig. 4i2l ). Khk-A depletion affected neither the ECAR nor the OCR of HIF1aDODD-expressing cells (Extended Data Fig. 4i ), while depletion of Khk-C did (Extended Data Fig. 4j ). In the absence of HIF1aDODD, neither Khk-A nor Khk-C depletion alone demonstrated any measurable effects on ECAR or OCR ( Supplementary Fig. 6g , h). In a converse experiment, overexpression of KHK-A alone had little, if any, effect on these parameters while KHK-C overexpression increased ECAR and decreased OCR (Extended Data Fig. 4k, l) . Thus, by stimulating fructose metabolism in cardiomyocytes, Khk-C expression promotes conversion of fructose carbon to lipids, suppresses mitochondrial oxidative phosphorylation and increases glycolysis.
Cardiac growth and dysfunction depends on Sf3b1
Next we assessed whether myocardial fructose and glucose uptake is induced in an in vivo model of cardiac hypertrophy (Extended Data Fig. 5a ). When TAC-treated and sham-operated control mice were simultaneously exposed to Fig. 5f, g ). In line with this, Glut5 expression was induced in these hypertrophy models (Extended Data Fig. 5h , i) in hearts of isoproterenol-treated mice and in left-ventricular biopsies of aortic stenosis and HCM-patients (Extended Data Fig. 5j-l ). In contrast, expression of aldose reductase (AKR1B1), which converts glucose to sorbitol in the polyol pathway, was not induced in the latter samples (Extended Data Fig. 5k, l) . Thus, cardiac hypertrophy is associated with increased fructose levels and uptake.
To study the Sf3b1-dependency of these phenomena in response to pathologic stress, we designed a viral-based vector system enabling ventricular-specific knockdown of Sf3b1 that is based on an AAV9 backbone containing a U6 promoter followed by a TATA-lox site, a CMV promoter driving eGFP, another TATA-lox site and shRNAs targeting Sf3b1 (Fig. 4a) . We constructed two viruses each expressing different shRNAs targeting Sf3b1 (AAV9-fl/fl-shSf3b1#1 and AAV9-fl/fl-shSf3b1#2). Validation of these recombinant viruses was performed both in vitro in NMCs and in vivo in Mlc2v-cre While injection of AAV9-fl/fl-shSf3b1#1 into Mlc2v-cre 1 or Mlc2v-cre 2 mice failed to cause any effects on ventricular size in sham-operated mice, AAV9-fl/fl-shSf3b1#1 injection protected Mlc2v-cre 1 but not Mlc2v-cre 2 littermates from 1K1C-induced cardiac hypertrophy (Fig. 4b ) and diastolic dysfunction (Fig. 4c and Extended Data Table 1) . Untargeted analysis of metabolites in NMCs treated as denoted. Depicted are metabolites with log 2 (fold change) . 0.5 and adjusted P value , 0.01 in at least one treatment group compared to corresponding control (n 5 4 biological replicates per group).
Like hypertrophic growth and function, the increase in fructose levels was also dependent on Sf3b1 (Fig. 4d) . Immunoblotting of lysates from these sham-or 1K1C-operated Mlc2v-cre 2 and Mlc2v-cre 1 mice confirmed that Sf3b1 was depleted where expected, preventing the generation of Khk-C isoform in ventricles of 1K1C-treated Mlc2v-cre 1 mice (Fig. 4e) . We also analysed the role of Sf3b1 in the TAC model. Application of both AAV9-fl/fl-shSf3b1#1 and AAV9-fl/fl-shSf3b1#2 viruses protected Mlc2v-cre 1 but not Mlc2v-cre 2 littermates from cardiac hypertrophy ( Fig. 4f ; Extended Data Fig. 5o and Extended Data Table 1 ) and systolic dysfunction ( Fig. 4g ; Extended Data Fig. 5p and Extended Data Table 1 ). Immunoblotting confirmed that Sf3b1 was downregulated and prevented the switch to the Khk-C isoform in response to TAC-induced pathologic stress in hearts of Mlc2v-cre 1 mice (Fig. 4h  and Extended Data Fig. 5q ). These results suggest that Sf3b1 is required for the development of pathologic cardiac hypertrophy.
Deletion of Khk protects from cardiac growth
To assess the importance of Khk-C in cardiac hypertrophy and function in the context of pathologic stress, we investigated two genetic mouse models, which were subjected to TAC and 1K1C stresses. Khk-A 2/2 mice only express Khk-C, whereas Khk-A/C 2/2 mice are deleted for both isoforms 21 . Exposure of wild-type and Khk-A 2/2 mice to TAC treatment induced cardiac hypertrophy and systolic dysfunction in both mouse strains (Extended Data Fig. 6a -e and Extended Data Table 2 ). ATP measurements in left ventricles of sham-or TAC-treated wild-type and Khk-A 2/2 mice revealed a reduction of ATP levels in hearts after TAC compared to control mice (Extended Data Fig. 6f ).
Hearts of Khk-A/C 2/2 mice, when exposed to TAC, did not display signs of hypertrophy or systolic dysfunction (Extended Data Fig. 6g -k and Extended Data Table 2 ). Moreover, ATP levels remained unchanged in Khk-A/C 2/2 mice exposed to TAC (Extended Data  Fig. 6l ). All TAC-treated hearts accumulated Hif1a and Sf3b1 in the left ventricle (Extended Data Fig. 6m, n) . Khk-C expression was only detectable in TAC-treated hypertrophied ventricles, but not in the corresponding hearts from Khk-A/C 2/2 mice (Extended Data  Fig. 6m, n) . Table 3 ) and diastolic dysfunction ( Fig. 5c and Extended Data Table 3 ). Hif1a and Sf3b1 levels were induced in left ventricles of both 1K1C-treated strains, whereas Khk-A expression in sham-treated control mice was depleted as expected (Fig. 5d) . Additional deletion of Khk-C protected hearts of these pathologies ( Fig. 5e-g 1/1 and Khk-A/C 2/2 mice processed for immunoblotting with antibodies as indicated. For a, c, e, g, *P , 0.05; **P , 0.01; ***P , 0.001; two-tailed unpaired t-test; number of mice per group is given in Extended Data Table 2 . Error bars are s.e.m. Table 1 . Error bars are s.e.m. *P , 0.05; **P , 0.01; two-tailed unpaired t-test (b-d, f, g). Data Fig. 6u, v) . In sum, only deletion of Khk-A in combination with Khk-C, but not Khk-A alone, prevents the development of pathologic growth and cardiac dysfunction upon different stresses.
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blood pressure was similar in these mouse strains following 1K1C treatment (Extended
Discussion
Our results demonstrate that fructose metabolism can be provoked in the heart by pathologic stimuli through HIF1a activation of SF3B1-mediated splicing of KHK pre-mRNA (Extended Data Fig. 7) . The potential general importance of these findings draw on the central role occupied by HIF1a in human disease, highlighting the HIF1a-SF3B1-KHK-C axis as a promising therapeutic target.
Splicing output of the HIF1a target SF3B1, which contributes to intron removal by anchoring pre-mRNA onto the spliceosome 12 , is sensitive to changes in the abundance of SF3B1 13, 22 . This feature of SF3B1 to expand and/or change splice target spectrum as a function of abundance may be exploited by HIF1a to affect KHK-C production. That the latter is less sensitive to changes in the levels of other factors of the U2snRNP complex investigated here implies that SF3B1 is either limiting for U2snRNP assembly/function or occupies a specific role in this context. Irrespective, this process is likely influenced by additional positive-and/or negative-acting factors, as has been demonstrated for PKM2 23 . The criticality of KHK-C function in pathologic cardiac growth may manifest at multiple levels. Unrestrained KHK-C-driven phosphorylation of fructose may limit ATP levels and thus restrict ATP-mediated negative feedback inhibition of PFK, facilitating high glycolytic flux 24 . The latter may be further enhanced by an increased availability of F1P, as this metabolite has been shown to induce glucokinase and pyruvate kinase, at least in the liver 25 . Apart from positively affecting glucose metabolism, KHK-C and fructose availability also increased nucleic acid, lipid and protein biosynthesis, which may support growth. Although our work points to a fructose-metabolismrelated function of KHK-C in cardiac hypertrophy, the source of fructose could, under certain circumstances, vary and originate alternatively from glucose 15 . In addition, yet-to-be-discovered functions of KHK-C unrelated to fructose metabolism (that may, for example, relate to gene regulatory activities) could contribute to cell growth control 26 . Biopsies of heart disease patients demonstrate increased expression of HIF1a, SF3B1 and KHK-C. Since aortic stenosis and diabetes are frequent comorbidities in senescent humans 27 and diabetic patients tend to have also higher fructose levels in serum 28 , the impact of the HIF1a-SF3B1-KHK-C axis in these patients might be particularly important. With respect to other disease states, SF3B1 is found recurrently mutated in human cancers 12 . It is conceivable that some of these cancer-associated mutations affect alternative splicing of KHK and fructose metabolism in cancer cells independent of hypoxia, thereby contributing to tumour development.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Table 4 ) and healthy controls. Additional left-ventricular biopsies were provided by W. Linke (University of Münster). Clinical and demographical data from the corresponding patients were previously published 29 . All procedures were in compliance with local ethical committees. An informed consent was obtained from all patients included in the study. Mouse strains. Khk-A 2/2 and Khk-A/C 2/2 mice were obtained from A. Asipu (University of Leeds) and R. Johnson (University of Colorado). MLC2v-cre line was from J. Chen (University of California). All mice were maintained in a conventional animal facility at RCHCI and EPIC, ETH Zürich. Maintenance and animal experimentation were in accordance with the Swiss Federal Veterinary Office (BVET) guidelines. Data presented in this manuscript represent studies with male mice. After baseline echocardiography mice were randomly distributed to sham or treatment groups. Animal surgeries and echocardiography was performed blinded, that is the involved veterinarian was not aware of the genotype of the mice before or during operation. Animal numbers for experiments were chosen based on expected mortality rates and phenotypical or functional changes of hearts in wild-type mice due to treatment/surgery. Animals were excluded from the study in case of death before the experimental endpoint or based on the evaluation of pain using a standardized score sheet, approved by BVET. One-kidney, one-clip. Six-to seven-week-old Khk-A
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Human ventricular biopsies. Left-ventricular tissues were obtained from patients with hypertrophic cardiomyopathy and aortic stenosis (Supplementary
2/2
, Khk-A/C 2/2 and corresponding Khk-A 1/1 and Khk-A/C 1/1 male mice with a pure C57/BL6J background as well as Mlc2v-cre 1 and Mlc2v-cre 2 male mice with a C57/BL6J 129S mixed background were anaesthetized and surgery was performed as previously described 10 by inhalation of isoflurane (4% in oxygen, 1 l min 21 ). A sham procedure, which included the entire surgery with the exception of artery clipping, was applied to control mice. Trans-aortic constriction. 10-12-week-old Khk-A
, Khk-A/C 2/2 and corresponding Khk-A 1/1 and Khk-A/C 1/1 male mice as well as Mlc2v-cre 1 and Mlc2v-cre 2 male mice were subjected to pressure overload by trans-aortic constriction (TAC) through constriction of the descending aorta as described 30 . The mice were monitored for 14-18 days after surgery, and their heart functions determined by echocardiography. In vivo isoproterenol delivery. Alzet model 2002 mini-osmotic pumps (Alzet) were filled with isoproterenol, and were set to deliver at 30 mg kg 21 per day for 14 days in C57/BL6J wild-type mice. Pumps were then implanted into 9210-weekold male mice under isoflurane anaesthesia as previously described 10 . Echocardiography. Transthoracic echocardiography was performed using a 30 MHz probe and the Vevo 770 Ultrasound machine (Visualsonics) under mild anaesthesia with 1.5% isoflurane as previously described 31 . Direct arterial blood pressure measurements in mice. The arterial blood pressure measurements in mice were performed as described previously 32 . Blood pressure was monitored for about 1 h in awake animals that were unconstrained. Isolation and maintenance of primary neonatal mouse cardiomyocytes. Isolation of neonatal mouse cardiomyocytes was performed as previously described 10 . Experiments involving HIF1a, SF3B1 and KHK-C were performed with maintenance medium supplemented with physiologic concentrations of glucose (5 mM) and fructose (25 mM). The medium was changed daily. Pharmacological treatment was done with phenylepinephrine at a concentration of 100 mM and with isoproterenol at 10 mM for 48 h before preparation of SDS samples or processing for RNA isolation. Lentivirus production and transduction. Lentiviral particles were produced in HEK-293T cells as previously described 33 . HEK-293T cells were purchased from American Type Culture Collection (ATCC) and regularly checked for mycoplasma contamination using a PCR-based myocoplasma detection kit (Sciencell). Cells were transduced with lentivirus 3 h after isolation by adding virus-containing supernatants to the cell culture medium and incubating cells at 37 uC/5% CO 2 overnight. Transient transfection. The pcDNA3 Sf3b1 construct was transiently transfected by using the Lipofectamin 2000 (Invitrogen) in 2-day-old NMCs according to the manufacturer's protocol. Cells were harvested and analysed 36 h after transfection. AAV9-fl/fl-shSf3b1. For the generation of the viral constructs, we cloned two shRNAs targeting Sf3b1 in a pSico vector where the U6 promoter driven shRNA expression is Cre-lox regulated 34 . The shRNA sequences were the following: AAV9-fl/fl-shSf3b1#1, sense (59239):TGCATCGTCCTCCAAAGATTTTCAA GAGAAATCTTTGGAGGACGATGCTTTTTTC, antisense (59239): TCGAG AAAAAAGCATCGTCCTCCAAAGATTTCTC TT GAAAATCTTTGGAGG ACGATGCA; AAV9-fl/fl-shSf3b1#2, sense (59239): TG CTGCCTTACGTC AGATTATTCAAGAGATAATCTGACGTAAGGCAGCTTTTTTC, antisense (59239): TCGAGAAAAAAGCTGCCTTACGTCAGATTATCTCTTGAATAA TCTGACGTAAGGCAGCA.
After in vitro validation of shRNA efficiency using AdenoCre expression to induce Cre-mediated recombination and activation of shSf3b1 expression, the region bearing the U6 promoter, the shRNA and the TATA-lox sites of the pSico construct was amplified and ligated into NheI/XhoI linearized AAV-bGH (1) vector. Viral amplification was done by Vectorbiolabs. AAV9 viruses were injected at a concentration of 1.2 3 10 13 genome copies (GC) per kg body weight into tail veins of Mlc2v-cre 1 or Mlc2v-cre 2 mice. Plasmid constructions. The pLenti-pgk-HIF1aDODD puro lentiviral expression vector was generated by subcloning the HIF1aDODD fragment from a pcDNA3-HA-HIF1aDODD(401-603) plasmid 35 as described previously 36 . The KHK-A and KHK-C overexpression constructs were generated by subcloning KHK-A and KHK-C from the pET11a-KHK-A and pET11a-KHK-C expression constructs (provided by A. Asipu) into the Gateway Entry vector pENTR1a and by LR-reaction in the pLenti-pgk-puro lentiviral expression vector. As a corresponding control the pLenti-pgk puro empty vector was used. SF3A3 and SF3B3 overexpression constructs were generated by subcloning SF3A3 (from human ORFeome 8.1 collection, Thermo Scientific) or SF3B3 (from Addgene, plasmid #11241) in the pLKO.1 CMV puro construct provided by A. Ittner (ETH Zürich), by using EcoRI and SalI (SF3A3) or EcoRI and MluI (SF3B3) restriction sites. As a control vector the empty pLKO.1 CMV puro construct was used. Since the wildtype coding sequence of Sf3b1 is toxic to bacteria, we used a codon optimized Sf3b1 to perform overexpression experiments (the DNA and amino acid sequence can be found in Supplementary Data 1) . First, we amplified Sf3b1 from mouse cDNA until the internal XhoI restriction site (121,568 bp) and subcloned it into a pcDNA3 vector by using EcoRI/XhoI restriction sites. The synthesis and codon optimisation of the second part (1,57823,915 bp) was performed by Genscript. Finally we subcloned the two parts of Sf3b1 by double ligation in a pcDNA3 vector by using EcoRI, XhoI and XbaI restriction sites. Sf3b1 promoter-luciferase construct. 1.5 kilobases (kb)of the Sf3b1 promoter was amplified from mouse BAC genomic DNA and cloned into the pGL3 luciferase reporter vector (Stratagene). HRE mutants of the respective promoters were generated by recombinant PCR 37, 38 . Sense and antisense primers were generated bearing HRE mutations, which were used to amplify the mutant 59 and 39 regions of the promoter, respectively. The 59 and 39 products generated from the respective PCR reactions were pooled afterwards at a 1:1 ratio and re-amplified using primers targeting the 59 and 39 ends of the respective promoters. To check for the correctness of the HRE mutation in the right direction, HRE mutants of the respective promoters were verified by sequencing (Microsynth). shRNA knockdown of Khk-A and Khk-C. Khk-A-or Khk-C-specific shRNAs were designed using the Life Technologies BLOCK-iT RNAi Designer online tool (Life Technologies), searching for 21mer targets of either Khk-A-or Khk-Cspecific transcripts. shRNAs were automatically compared to the mouse database using BLAST. As a loop sequence, the TRC-library loop sequence TCTGAG was used. Per isoform, three different shRNAs were chosen as promising, according to the program's algorithm and cloned into the pLKO.1 lentiviral vector. The presence of the shRNA was confirmed by sequencing (Microsynth). shRNAs were then tested in NMCs for knockdown efficiency and specificity for either Khk-A or Khk-C. After validation, shRNAs shKhk-A#3, referred as shKhk-A and shKhk-C#2, referred as shKhk-C were chosen for all experiments described. The sequences are as follows: shKhk-A, sense (59-39): CCGGGATGACCTCCGCC AACAT TCTCTCGAGAGAATGTTGGCGGAGGTCATCTTTTTG; shKhk-C, sense (59-39): CCGGGCTCTTGCTGCATCGTCAACACTCGAGTGTTGAC GATGCAGCAAGAGC TTTTTG. TRC lentiviral shRNA constructs. For lentiviral shRNA mediated knockdown the following shRNAs from the TRC library were used in a pLKO.1 construct: Sf3b1 (shSf3b1#1, TRCN0000295293; shSf3b1#2, TRCN0000295294), Sf3a3 (shSf3a3#1, TRCN0000285834; shSf3a3#2, TRCN0000277028), Sf3b2 (shSf3b2#3, TRCN0000123811; shSf3b2#4, TRCN0000123812), Sf3b3 (shSf3b3#5, TRCN0000311577; shSf3b3#11 TRCN0000109223), Glut5 (shGlut5#4, TRCN0000079392; shGlut5#, TRCN0000079388), Hif1a (shHif1a, TRCN0000232220), Khk (shKhk, TRCN0000416511). As a non-targeting shRNA construct the pLKO.1 vector SHC002 (Sigma) was used. RNA-isolation and reverse transcription. RNA was isolated with the RNeasy Mini Kit (Qiagen) and reverse-transcribed using a EcoDry Premix (OligoDT) (Clontech) according to the manufacturer's instructions. Splice-junction microarrays. Total RNA was isolated from NMCs infected with shNs and shHif1a lentiviruses and cultured in either 21% or 3% O 2. . In another experiment NMCs were transduced with shNs and shSf3b1 lentiviruses and cultured at 3% O 2 before RNA was isolated. Complementary DNA samples were prepared using the GeneChip WT cDNA Synthesis and Amplification Kit (Affymetrix). cDNA was hybridized to AltSplice splice-junction microarrays and resulting data were analysed with version 3 of ASPIRE software as previously described 39 . The unprocessed cel files with microarray data are available from ArrayExpress with accession numbers E-MTAB-2652 and E-MTAB-3203, respectively. Luciferase assays. The luciferase assay was performed from material of NMCs using a luciferase kit (Promega) as recommended by the manufacturer and analysed on the MicroLumatPlus LB 96V (Berthold Technologies). Chromatin and RNA immunoprecipitations. ChIP assays were performed with material from NMCs and the assays carried out using the ChIP-IT Kit (Active Motif) according to the manufacturer's instructions. ChIP was performed with a ChIP-grade antibody from Abcam. In silico promoter analyses were performed using MatInspector and DiAlignTF (Genomatix). Sequences of primers used are 59-TTTCGCTGGCTTTTTAAGGA-39 and 59-ATCTTCGCCATTTTGTCCAC-39.
RNA immunoprecipitation assays were performed with material from NMCs using a RNA-ChIP-IT kit from Active Motif as recommended by the manufacturer. RNA immunoprecipitation was performed using a Sf3b1 antibody from MBL International. Sequences of primers used to detect potential binding of Sf3b1 on the branch points of Khk-A and Khk-C are the following: branch point primer for Khk-A, 59-CTACTTCCCTCTGCTCAGCC-39 and 59-GGTCATCC AGGACAAAATGC-39; branch point primer for Khk-C, 59-GGACCCTTC TTCTCTGAGGC-39 and 59-CACTTGAGACACATCCACGC-39. Immunoblotting. Dissected hearts and NMCs lysates were homogenized by freeze slamming and solubilized in a modified SDS sample buffer sonicated and boiled for 5 min 40 ). Protein lysates were resolved on 8%, 10% or 15% polyacrylamide minigels (BioRad) and transferred onto nitrocellulose membrane (GE Healthcare) by wet or semi-dry transfer. The following antibodies were used for immunoblotting rabbit HIF1a (catalogue no. NB-100-47; Novus Biologicals), a rabbit SF3B1 (catalogue no. ab172634; Abcam), a rabbit-KHK (catalogue no. HPA007040; Sigma), a rabbit KHK-C (custom made by Eurogentec) a rabbit Cre (catalogue no. 69050; Novagen), a rabbit SF3A3 (catalogue no. ab140605), a mouse SF3B2 (catalogue no. ab56800), a rabbit SF3B3 (catalogue no. NBP2-20258) mouse a-actinin (catalogue no. A7811; Sigma) and a chicken-GFP (catalogue no. GFP-1020; Aves Labs). Immunodetection and visualization of signals by chemiluminescence was carried out as described 40 , or by using the ImageQuant LAS 4000 mini (GE Healthcare). Immunoblots for Khk-A/C and Khk-C were visualized using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific). Ketohexokinase splicing assay I. This Khk splicing assay including amplification of part of the Khk cDNA and the identified alternative spliced region was adapted from a splice assay for PKM1/M2 isoforms 23 . RNA isolated from NMCs transduced with shNs or shSf3b1 lentiviruses after treatment with isoproterenol or HIF1aDODD and RNA isolated from sham-or 1K1C-treated wild-type left ventricles was reverse-transcribed then amplified using a forward primer (59-GAAGCAGATCCTGTGCGTG-39) that bound to shared Khk A/C exon 1 and a reverse primer (59-ATTGTGCTCCTCTATCCGC-39) that bound to shared Khk A/C exon 5 sequences. The 468-bp PCR products representing both Khk-A and Khk-C transcripts were then digested with HincII and run on a 1.5% agarose gel, after which the 468 bp (uncut Khk-A-specific amplicon), 294 bp and 174 bp (HincII-cleaved Khk-C-specific amplicon) products were quantitated using ImageJ software. Ketohexokinase splicing assay II. To analyse KHK isoforms in human and mouse hearts or NMCs RT-PCR was performed. Total RNA was isolated from hearts or NMCs and reverse-transcribed into cDNA using the RNA to cDNA EcoDry Premix (OligoDT) kit (Clontech). Full length KHK-A/C cDNA was amplified by RT-PCR, loaded onto an agarose gel and purified by gel extraction. One hundred nanograms of full-length KHK-A/C cDNA was used as a template to amplify KHK-A and KHK-C specific fragments, respectively, using primer pairs consisting of a common KHK A/C forward and KHK-A-or KHK-C-specific reverse primer set. To be able to distinguish between KHK-A and KHK-C isoforms, the corresponding amplicons differed in length. The influence of fragment length on fragment amplification was minimised by designing two sets of primer pairs for each isoform (primer set 1 vs primer set 2): Khk-A 1 , Khk-C 1 and Khk- Ketohexokinase activity assay. The ketohexokinase activity assay 41 was modified by adding Roche Complete Protease Inhibitor Cocktail and Roche PhosSTOP to the reaction mixture, addition of 140 mg NMCs protein per reaction and incubating for 2 h at 37 uC. Spectrophotometric absorbance measurements of the remaining fructose were performed in 96-well plates at 515 nm using a Spectra MAX 190 plate reader (Molecular Devices). Wild-type liver protein was used as a positive control and reactions without protein were used as negative controls. Metabolomics. 4 3 10 5 NMCs were cultured per 3-cm dish. Cells were washed with PBS and whole-cell culture plates were snap frozen on dry ice. Metabolites were extracted twice from plates with hot (75 uC) 70% ethanol. Targeted analysis of hexose-phosphates levels and of their 13 C-labelling pattern was performed by ion-pairing, reverse phase, ultra-performance liquid chromatographytandem mass spectrometry on a Thermo Quantum Ultra instrument (Thermo Scientific) 42 . Technical quadruplicates were merged using their mean. Untargeted analysis of metabolites was performed by flow injection-time-offlight mass spectrometry on a Agilent 6550 Instrument in negative mode 4 GHz, high resolution in a m/z range of 50-1,000 as reported earlier 43 . Ions were annotated to ionic derivatives of the metabolites listed in the KEGG database (organism hsa) using 0.001 atomic mass units (a.m.u.) tolerance. Data processing and analysis was done with Matlab. Immunofluorescent stainings. Immunofluorescent stainings were performed as described previously 10 . Cells were permeabilized and incubated with sarcomeric a-actinin antibody (Sigma) diluted 1:500 in 2% horse serum, 0.025% TritonX-100/PBS overnight at 4 uC. Cells were washed with PBS and incubated with 49,6-diamidino-2-phenylindole (DAPI), Phalloidin and AlexaFluor488 anti-mouse secondary antibody for 1 h at room temperature. Afterwards, stainings were washed and mounted in Lisbeth medium. 44 . Cells were counted in a Neubauer chamber after trypsinization and scintillation counts were normalized to absolute cell number. ) was applied to sham-or TAC-treated C57/Bl6 J mice at 3 weeks post operation by oral gavage. After 45 min animals were weighed and euthanized. Denoted organs were collected and weighed. Tissue was digested with 4 M ethanolic KOH, radioactivity was measured in a Beckman LS6500 scintillation counter (Beckman) and calculated as disintegrations per minute (d.p.m.) per mg tissue weight. Fructose content. Heart fructose content was measured using the fructose colorimetric/fluorometric assays kit according manufacturer's instructions (Biovision) and as described previously 45 . ) overnight. NMCs were washed three times with PBS before cell lysis was performed with 0.7 ml TRIzol (Invitrogen). Fractionation into RNA, DNA and protein was performed according to the manufacturer's instructions with adaptations of the volumes according to the starting volume. ADP/ATP Assay. 5 3 10 4 NMCs were cultured in a 96-well format and treated as denoted. After 3 days in culture NMCs were analysed using a Bioassay Systems Enzylight ATP:ADP ratio kit (ELDT-100, Bioassay Systems) according to manufacturer's instructions. Cellular ATP from 10 ml of lysate reacted with D-luciferin to generate a light signal that was proportional to the intracellular ATP concentration. In a second step, ADP was converted to ATP by an enzymatic reaction, and reacting with D-luciferin as in the first step. Luminometry was analysed using a MicroLumatPlus LB 96V (Berthold Technologies). Myocardial ATP content. The level of myocardial ATP was measured by using a colorimetric/fluorometric assay kit (Abcam) according to the manufacturer's instructions. Left-ventricular samples of about 10 mg weight were used as a starting material. The absorbance was read at 550 nm using a Tecan Infinite M1000 Pro plate reader and ATP content was calculated based on a standard curve generated from ATP-standards on the same 96-well plate. Values were normalized to protein concentrations obtained from Bradford assays. ) was added to the medium. On day 4, cells were washed twice with PBS and lipids were extracted by hexane-isopropanol extraction 46 . Protein concentration was measured by BCA protein assay and radioactivity count was normalized to protein content. Oil Red O staining. Oil Red O staining was combined with immunofluorescence according to a protocol in ref. 47 . Spot-detection was performed with the Anchor image analysis platform (http://www.microscopyimages.org/). Nuclei are segmented by first thresholding the (Gaussian-blurred) DAPI channel with Otsu's method, and then a watershed segmentation on the inverted Euclidian distance transform. Neighbouring segments are merged to increase an ellipticity score. A merge occurs if: ell(xy) . 0.5[ ell(x) 1 ell(y)], where xy is the merge of segments x and y. Segments with an area .50 mm 2 are deemed nuclei. Cells are segmented by thresholding the histogram-stretched FITC channel, combining with the nuclei binary-image, and performing ultimate erosion using the segmented nuclei as seeds. Spots are segmented by first performing rolling-ball background correction, thresholding, and then a watershed segmentation on the inverted intensity after median filtering. Segments with an area .0.2 mm 2 and a minimum gradient signal are deemed spots.
ARTICLE RESEARCH
Nile red staining. 4 3 10 5 NMCs were incubated with 0.25 mM oleic acid (Sigma-Aldrich) overnight and stained with 10 mg ml 21 Nile red (SigmaAldrich) for 10 min in PBS 48 . Values were normalized to cell number. Cell size quantification. NMCs were stained after 3 days of culturing for sarcomeric a-actinin (1:500, Sigma), phalloidin and DAPI. Pictures of all channels were taken using a 203 magnification. Using the software Cell Profiler, sarcomeric a-actinin-positive cells were identified and cell area was quantified. Multinucleated cells were counted manually and average area per cell was corrected taking into account the number of multi-nucleated cells. Measurements of extracellular acidification and oxygen consumption rate. 1 3 10 5 NMCs per well were seeded in a 24-well Seahorse cell culture plate (SeaHorse Bioscience) and assayed at day 3. ECAR and OCR were measured in parallel using a SeaHorse XF24 Flux Analyzer (SeaHorse Bioscience) in NMCs incubated in low-buffered Krebs-Henseleit buffer, supplemented with glucose (5 mM) and fructose (25 mM). After five consecutive basal measurements of ECAR to measure glycolysis related lactate production, 0.25 mM oleic acid was added and oxygen consumption rates were measured again for five consecutive times. Finally, 1 mM carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone was injected to stimulate maximal OCR in NMCs, reflecting mitochondrial reserve capacity. Statistical analysis. For statistical analyses, unpaired, two-tailed Student's t-tests (Excel) or one-way ANOVA analyses followed by a Dunnet's multiple comparison post-test were used as indicated in the respective figure legends. No statistical methods were used to predetermine sample size. Fig. 1c . Splicing is quantified as percent of the Khk-C isoform (%Khk-C). g, RT-PCR based assessment of Khk-A and Khk-C isoform expression as done in Fig. 1 g. h, i, Ventricular samples of sham-or 1K1C-operated mice were analysed for Khk isoform expression (h) as done in Fig. 1 g or Sf3b1, Khk-A and Khk-C mRNA expression (i) by qPCR; n 5 6 for each group. j, k, Ventricular samples of sham-or TAC-treated mice (j) and NaCl-or isoproterenol-treated mice (k) were analysed for expression of Sf3b1, Khk-A and Khk-C mRNA expression by qPCR (n 5 6 for each individual group). l, NMCs transduced as specified were validated for protein expression of indicated proteins by using immunoblots. In addition lysates of NMCs overexpressing KHK-A or KHK-C were processed for immunoblotting Khk antibodies. m, n, Ventricular samples of sham-or TAC-treated (m) and sham-or isoproterenol-treated mice (n) were analysed for indicated proteins by immunoblotting. o, Probes from left ventricles of 1K1C-, TAC-or isoproterenol-treated mice and their corresponding controls were analysed for mRNA expression of Hif1a targets. All values were presented in relation to sham-operated controls set as 1.0 (n 5 6 for each individual group). p, q, Leftventricular biopsies of HCM patients and healthy controls were analysed for mRNA expression of SF3B1, KHK-A and KHK-C (p) and HIF1a targets (q). All values are presented in relation to healthy controls set as 1. . (a, b, h-o, r) or s.e.m. (p, s-z) . *P , 0.05; **P , 0.01; ***P , 0.001. Two-tailed unpaired t-test (b, t, u, w-z). One-way ANOVA followed by Dunnett's multiple comparison post-test (a, h-p, r).
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